The Combination of Ibrutinib with BH3 Mimetics or Dichloroacetate Is Effective in B-CLL

Since its discovery, the BTK inhibitor ibrutinib has redefined the standard treatments for hematological cancers, such as chronic lymphocytic leukemia (CLL). However, concerns exist regarding its secondary effects in humans and its occasional lack of efficacy in certain malignancies. Therefore, comb...

Full description

Bibliographic Details
Published in:Cells
Main Authors: Joaquín Marco-Brualla, Oscar Gonzalo, Gemma Azaceta, Isabel Izquierdo, Luis Palomera, Martín Villalba, Isabel Marzo, Alberto Anel
Format: Article
Language:English
Published: MDPI AG 2025-08-01
Subjects:
B-CLL
dichloroacetate
BH3 mimetics
ibrutinib
Bcl-XL
Mcl-1
Online Access:https://www.mdpi.com/2073-4409/14/17/1343

Internet

https://www.mdpi.com/2073-4409/14/17/1343

Similar Items